CorMedix Inc. cash flow to debt ratio of 117.55% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

CorMedix Inc.'s free cash flow has increased -440.60% from $-50.73M last year to $172.79M, signaling increasing performance

CorMedix Inc.'s debt to equity ratio is 0.34, which means that the company's assets are healthy financed, signaling financial stability.

CorMedix Inc.'s debt has increased relative to shareholder equity from 0.01 last year to 0.34 today, signaling weakened financials

CorMedix Inc. has a net cash position, so leverage is healthy.

CorMedix Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

CorMedix Inc.'s profit margin has increased (-209.70%) in the last year from -41.24% to 45.25%, signaling increasing performance

CorMedix Inc.'s short-term assets of $367.05M exceed its short-term liabilities of $174.27M

CorMedix Inc.'s return on assets of 22.19% is higher than the 5.00% threshold, indicating efficient asset utilization

CorMedix Inc.'s return on equity of 50.38%, is higher than 15.00%, indicating good performance

CorMedix Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

CorMedix Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

CorMedix Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

CorMedix Inc. has a free cash flow yield of 29.25%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

CorMedix Inc.'s yearly earnings has increased -1.01K% since last year from $-17.93M to $163.06M, signaling increasing performance

CorMedix Inc.'s yearly revenue has increased 617.03% since last year from $43.47M to $311.71M, signaling increasing performance

ROIC 27.59% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

CorMedix Inc.'s 3-year revenue CAGR of 1.58K% is positive, indicating growing revenue over the past 3 years

CorMedix Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

CorMedix Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

CorMedix Inc. has insufficient data to evaluate this check.

CorMedix Inc. has an earnings yield of 30.23%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

CorMedix Inc. is undervalued relative to its fair value price of 14.59 based on EBITDA multiple model

CorMedix Inc. has an EV/EBITDA ratio of 3.52x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

CorMedix Inc. is overvalued relative to its fair value price of -5.81K based on Earnings Fair Value model

CorMedix Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

CorMedix Inc. has a price-to-book ratio of 1.37x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

CorMedix Inc. has a price-to-sales ratio of 1.50x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue